Sun et al. revealed that propofol exerted antiproliferative action on TNBC cells and that three propofol-related agents, including propofol, fospropofol disodium and propofol injectable emulsion, all significantly amplified the efficacy of DOX in TNBC and that the RCD effects involved not only apoptosis but also ferroptosis mechanisms, including altered mitochondrial morphology, accumulated iron in tumour cells and elevated ROS levels, along with corresponding modification of the p53/SLC7A11 pathway [69] (Fig. 3). Here, SLC7A11 is linked to neoplasm.